Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab and Gemcitabine for High-Risk NMIBC After TURBT
NCT07808216Phase 2Not yet recruiting
- Sponsor
- Tianjin First Central Hospital
- Start
- Oct 2026
- Primary completion
- Oct 2028
01
Overview
A Phase 2 trial of toripalimab in non-muscle-invasive bladder cancer (NMIBC), sponsored by Tianjin First Central Hospital. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
toripalimab
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT07808216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07808216.